STING1 and neoplasm: In Hepa1-6 tumor-bearing mice models, the survival time of the STING + αPD-1 dual immunotherapy, STING + αLAG-3 dual immunotherapy, and αPD-1 + αLAG-3 dual immunotherapy groups were 55, 49, and 49 days, respectively.